Literature DB >> 19398312

Efficacy of photodynamic therapy as a treatment for Gorlin syndrome-related basal cell carcinomas.

J Loncaster1, R Swindell, F Slevin, L Sheridan, D Allan, E Allan.   

Abstract

AIMS: The management of the multiple basal cell carcinomas (BCCs) that develop throughout life of patients with Gorlin syndrome can be challenging. Surgical excision can result in significant disfigurement from scarring and tissue defects. Radiotherapy is contraindicated because of enhanced radiation tumourigenesis in these patients. Photodynamic therapy (PDT) is a simple, repeatable out-patient procedure, which is associated with minimal skin deterioration. It is now routinely used to treat superficial sporadic BCCs, using a topically-applied photosensitiser and external light, but its role in the management of Gorlin syndrome-related BCCs has yet to be established. In particular, Gorlin syndrome is often associated thick, nodular lesions which can be resistant to treatment with topical PDT.
MATERIALS AND METHODS: We report our outcome data for 33 Gorlin patients (138 lesions) treated with PDT. Lesion thicknesses were assessed using ultrasound, both prior to treatment and during follow-up, to quantify treatment response and to guide the choice of treatment methods. Topical PDT was used to treat superficial lesions (<2 mm thick) and a systemic photosensitiser +/- light delivered by interstitially-placed optical fibres was employed for thicker lesions (>2 mm). RESULTS AND
CONCLUSIONS: Local control rates of 56.3% at 12 months were achieved overall. The use of a systemic photosensitiser +/- interstitial light delivery extended the remit of PDT, allowing thicker lesions (>2 mm) to be treated, resulting in local control rates of 59.3% in this group. PDT can be considered as a treatment option for patients with multiple BCCs as a result of Gorlin syndrome. The use of ultrasound to accurately assess lesion thickness helps to select the optimum treatment method. Systemic photosensitisers and interstitial optical fibres can be used to treat thicker lesions, offering a treatment option for patients with thick nodular tumours who wish to avoid surgery.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19398312     DOI: 10.1016/j.clon.2009.03.004

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  7 in total

Review 1.  A Surgical View of Photodynamic Therapy in Oncology: A Review.

Authors:  K Moghissi; Kate Dixon; Sally Gibbins
Journal:  Surg J (N Y)       Date:  2015-10-15

2.  Nevoid Basal Cell Carcinoma Syndrome: A Long-Term Study in a Family.

Authors:  Thiago de Santana Santos; André Vajgel; Paulo Ricardo Saquete Martins-Filho; Almir Walter de Albuquerque Maranhao Filho; Ricardo José De Holanda Vasconcellos; Riedel Frota; José Rodrigues Laureano Filho
Journal:  Craniomaxillofac Trauma Reconstr       Date:  2015-08-03

Review 3.  Photodynamic Therapy and Non-Melanoma Skin Cancer.

Authors:  Liezel L Griffin; John T Lear
Journal:  Cancers (Basel)       Date:  2016-10-22       Impact factor: 6.639

4.  Improvement of Basal Cell Carcinomas in Patients with Nevoid Basal Cell Carcinoma Syndrome Following by 5-Aminolevulinic Acid Photodynamic Therapy: A Case Report.

Authors:  Yan Jing Chen; Qin Yi; Yi Ming Li; Li Li
Journal:  Clin Cosmet Investig Dermatol       Date:  2021-12-16

Review 5.  Xeroderma Pigmentosum: A Genetic Condition Skin Cancer Correlated-A Systematic Review.

Authors:  Tito Brambullo; Michele Rosario Colonna; Vincenzo Vindigni; Stefano Piaserico; Giuseppe Masciopinto; Mariarosaria Galeano; Alfio Luca Costa; Franco Bassetto
Journal:  Biomed Res Int       Date:  2022-07-18       Impact factor: 3.246

Review 6.  Photodynamic therapy in pediatric age: Current applications and future trends.

Authors:  Luca Di Bartolomeo; Domenica Altavilla; Mario Vaccaro; Federico Vaccaro; Violetta Squadrito; Francesco Squadrito; Francesco Borgia
Journal:  Front Pharmacol       Date:  2022-08-16       Impact factor: 5.988

7.  Effects of photodynamic therapy on dermal fibroblasts from xeroderma pigmentosum and Gorlin-Goltz syndrome patients.

Authors:  Alicia Zamarrón; Marta García; Marcela Del Río; Fernando Larcher; Ángeles Juarranz
Journal:  Oncotarget       Date:  2017-08-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.